Orbimed Advisors LLC insider trades
Orbimed Advisors LLC has filed 59 Form 4s with the SEC that we hold, for Passage BIO, Inc. (PASG) (10% owner), Sionna Therapeutics, Inc. (SION) (Director), NeuroPace Inc (NPCE) (10% owner) and ALPN (Director), among 32 companies in all. Across all of them we count 40 purchases worth $168.3M and 82 sales worth $144.9M reported on Form 4. In the last 12 months: 8 purchases ($91.2M) and 20 sales ($104.4M). The largest single trade was a sale of 787,024 shares of Enliven Therapeutics, Inc. worth $35.7M, dated 2026-06-22. The first filing on our record is dated 2021-07-06 and the latest 2026-09-30.
Passage BIO, Inc. (PASG)
10% owner · 7 filings · 16 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-01-20 | P, purchase reported on Form 4 | 50,800 | $254.0K | 2022-05-05 |
| 2023-06-27 | P, purchase reported on Form 4 | 617,382 | $518.6K | 2023-06-29 |
| 2023-06-28 | P, purchase reported on Form 4 | 575,195 | $483.2K | 2023-06-29 |
| 2024-09-19 | S, sale reported on Form 4 | 39,300 | $27.9K | 2024-09-23 |
| 2024-12-09 | S, sale reported on Form 4 | 54,181 | $45.5K | 2024-12-11 |
| 2024-12-10 | S, sale reported on Form 4 | 8,015 | $6.4K | 2024-12-11 |
| 2024-12-11 | S, sale reported on Form 4 | 80 | $64 | 2024-12-11 |
| 2025-01-10 | S, sale reported on Form 4 | 126,209 | $83.3K | 2025-01-14 |
| 2025-01-13 | S, sale reported on Form 4 | 17,986 | $11.5K | 2025-01-14 |
| 2025-01-14 | S, sale reported on Form 4 | 79,024 | $47.4K | 2025-01-14 |
| 2025-04-22 | S, sale reported on Form 4 | 78,049 | $26.5K | 2025-04-24 |
| 2025-04-23 | S, sale reported on Form 4 | 89,328 | $30.4K | 2025-04-24 |
| 2025-04-24 | S, sale reported on Form 4 | 68,195 | $21.8K | 2025-04-24 |
| 2025-06-24 | S, sale reported on Form 4 | 231,600 | $81.1K | 2025-06-26 |
| 2025-06-25 | S, sale reported on Form 4 | 138,800 | $45.8K | 2025-06-26 |
| 2025-06-26 | S, sale reported on Form 4 | 213,257 | $70.4K | 2025-06-26 |
Sionna Therapeutics, Inc. (SION)
Director · 7 filings · 14 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-11-24 | S, sale reported on Form 4 | 94,583 | $4.2M | 2025-11-26 |
| 2025-11-25 | S, sale reported on Form 4 | 11,890 | $530.3K | 2025-11-26 |
| 2025-11-26 | S, sale reported on Form 4 | 1,600 | $71.2K | 2025-11-26 |
| 2026-04-14 | S, sale reported on Form 4 | 47,814 | $2.1M | 2026-04-16 |
| 2026-04-15 | S, sale reported on Form 4 | 235,863 | $10.5M | 2026-04-16 |
| 2026-04-16 | S, sale reported on Form 4 | 226,906 | $10.3M | 2026-04-16 |
| 2026-04-17 | S, sale reported on Form 4 | 52,397 | $2.3M | 2026-04-21 |
| 2026-04-18 | S, sale reported on Form 4 | 2,948 | $131.2K | 2026-04-21 |
| 2026-05-07 | S, sale reported on Form 4 | 48,546 | $2.2M | 2026-05-11 |
| 2026-05-08 | S, sale reported on Form 4 | 59,767 | $2.7M | 2026-05-11 |
| 2026-05-11 | S, sale reported on Form 4 | 184,639 | $8.5M | 2026-05-11 |
| 2026-05-27 | S, sale reported on Form 4 | 101 | $4.5K | 2026-05-29 |
| 2026-06-30 | S, sale reported on Form 4 | 115,844 | $5.3M | 2026-07-02 |
| 2026-07-07 | S, sale reported on Form 4 | 85,918 | $3.9M | 2026-07-09 |
NeuroPace Inc (NPCE)
10% owner · 4 filings · 9 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-04-19 | S, sale reported on Form 4 | 18,253 | $255.9K | 2024-04-23 |
| 2024-04-22 | S, sale reported on Form 4 | 24,609 | $345.8K | 2024-04-23 |
| 2024-04-23 | S, sale reported on Form 4 | 21,791 | $311.4K | 2024-04-23 |
| 2024-04-24 | S, sale reported on Form 4 | 1,781 | $25.0K | 2024-04-26 |
| 2024-05-01 | S, sale reported on Form 4 | 15,690 | $220.0K | 2024-05-03 |
| 2024-05-02 | S, sale reported on Form 4 | 8,842 | $123.9K | 2024-05-03 |
| 2024-05-03 | S, sale reported on Form 4 | 4,674 | $65.6K | 2024-05-03 |
| 2025-05-14 | S, sale reported on Form 4 | 34,000 | $542.0K | 2025-05-16 |
| 2025-05-14 | S, sale reported on Form 4 | 134,136 | $2.1M | 2025-05-16 |
ALPN
Director · 3 filings · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-09-17 | P, purchase reported on Form 4 | 425,531 | $4.0M | 2021-09-21 |
| 2021-09-17 | P, purchase reported on Form 4 | 585,106 | $5.5M | 2021-09-21 |
Adicet Bio, Inc. (ACET)
10% owner · 2 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-06-27 | P, purchase reported on Form 4 | 58,000 | $121.2K | 2023-06-29 |
| 2023-06-27 | P, purchase reported on Form 4 | 442,000 | $923.8K | 2023-06-29 |
| 2023-06-27 | P, purchase reported on Form 4 | 250,000 | $522.5K | 2023-06-29 |
| 2023-06-27 | P, purchase reported on Form 4 | 125,000 | $261.2K | 2023-06-29 |
| 2025-10-08 | P, purchase reported on Form 4 | 1,500,000 | $1.5M | 2025-10-10 |
| 2025-10-08 | P, purchase reported on Form 4 | 3,500,000 | $3.5M | 2025-10-10 |
Compass Therapeutics, Inc. (CMPX)
Director, 10% owner · 2 filings · 4 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-05-11 | P, purchase reported on Form 4 | 64,700 | $115.8K | 2022-05-13 |
| 2022-05-12 | P, purchase reported on Form 4 | 97,094 | $228.2K | 2022-05-13 |
| 2022-05-13 | P, purchase reported on Form 4 | 30,722 | $76.5K | 2022-05-13 |
| 2022-11-08 | P, purchase reported on Form 4 | 402,000 | $1.3M | 2022-11-10 |
Disc Medicine, Inc. (IRON)
Director · 2 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-02-15 | P, purchase reported on Form 4 | 14,329 | $329.6K | 2023-02-17 |
| 2023-02-15 | P, purchase reported on Form 4 | 57,318 | $1.3M | 2023-02-17 |
| 2023-02-15 | P, purchase reported on Form 4 | 37,049 | $852.1K | 2023-02-17 |
| 2025-03-24 | S, sale reported on Form 4 | 756 | $40.9K | 2025-03-26 |
| 2025-03-24 | S, sale reported on Form 4 | 3,026 | $163.7K | 2025-03-26 |
| 2025-03-24 | S, sale reported on Form 4 | 1,956 | $105.8K | 2025-03-26 |
Enliven Therapeutics, Inc. (ELVN)
10% owner · 2 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-06-15 | S, sale reported on Form 4 | 9,086 | $409.1K | 2026-06-17 |
| 2026-06-15 | S, sale reported on Form 4 | 272,322 | $12.3M | 2026-06-17 |
| 2026-06-22 | S, sale reported on Form 4 | 24,846 | $1.1M | 2026-06-24 |
| 2026-06-22 | S, sale reported on Form 4 | 46,776 | $2.1M | 2026-06-24 |
| 2026-06-22 | S, sale reported on Form 4 | 787,024 | $35.7M | 2026-06-24 |
| 2026-06-22 | S, sale reported on Form 4 | 1,477 | $66.5K | 2026-06-24 |
ImageneBio, Inc. (IKNA)
Director · 2 filings · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
RPTX
Director · 2 filings · 10 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-08-17 | S, sale reported on Form 4 | 16,886 | $576.2K | 2021-08-19 |
| 2021-08-17 | S, sale reported on Form 4 | 512 | $17.5K | 2021-08-19 |
| 2021-08-18 | S, sale reported on Form 4 | 78 | $2.7K | 2021-08-19 |
| 2021-08-18 | S, sale reported on Form 4 | 2,852 | $96.9K | 2021-08-19 |
| 2021-08-31 | S, sale reported on Form 4 | 8,223 | $279.1K | 2021-09-02 |
| 2021-08-31 | S, sale reported on Form 4 | 249 | $8.5K | 2021-09-02 |
| 2021-09-01 | S, sale reported on Form 4 | 12,586 | $427.7K | 2021-09-02 |
| 2021-09-01 | S, sale reported on Form 4 | 382 | $13.0K | 2021-09-02 |
| 2021-09-02 | S, sale reported on Form 4 | 15,941 | $545.8K | 2021-09-02 |
| 2021-09-02 | S, sale reported on Form 4 | 483 | $16.5K | 2021-09-02 |
SWTX
10% owner · 2 filings · 3 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-01 | S, sale reported on Form 4 | 15,959 | $1.4M | 2021-07-06 |
| 2022-08-08 | S, sale reported on Form 4 | 205,000 | $7.9M | 2022-08-10 |
| 2022-08-09 | S, sale reported on Form 4 | 69,568 | $2.6M | 2022-08-10 |
TELA Bio, Inc. (TELA)
10% owner · 2 filings · 6 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-04-19 | S, sale reported on Form 4 | 136,000 | $1.3M | 2023-04-21 |
| 2023-04-20 | S, sale reported on Form 4 | 28,300 | $266.9K | 2023-04-21 |
| 2023-04-21 | S, sale reported on Form 4 | 27,700 | $260.7K | 2023-04-21 |
| 2024-06-28 | S, sale reported on Form 4 | 378,000 | $1.8M | 2024-07-02 |
| 2024-07-01 | S, sale reported on Form 4 | 13,700 | $64.1K | 2024-07-02 |
| 2024-07-02 | S, sale reported on Form 4 | 36,600 | $166.2K | 2024-07-02 |
THRX
Director, 10% owner · 2 filings · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-07-17 | P, purchase reported on Form 4 | 328,482 | $1.0M | 2023-07-19 |
| 2023-07-17 | P, purchase reported on Form 4 | 151,450 | $461.9K | 2023-07-19 |
TSBX
Director · 2 filings · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-07-20 | P, purchase reported on Form 4 | 416,666 | $5.0M | 2023-07-24 |
ADARx Pharmaceuticals, Inc. (ADRX)
Director, 10% owner · 1 filing · 3 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-09-28 | P, purchase reported on Form 4 | 300,249 | $5.1M | 2026-09-30 |
| 2026-09-28 | P, purchase reported on Form 4 | 61,516 | $1.0M | 2026-09-30 |
| 2026-09-28 | P, purchase reported on Form 4 | 588,235 | $10.0M | 2026-09-30 |
AFIB
Director, 10% owner · 1 filing · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-07-19 | P, purchase reported on Form 4 | 714,285 | $10.0M | 2021-07-21 |
| 2021-07-19 | P, purchase reported on Form 4 | 357,143 | $5.0M | 2021-07-21 |
BlossomHill Therapeutics, Inc. (BLSM)
Director · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-08-10 | P, purchase reported on Form 4 | 625,000 | $10.0M | 2026-08-12 |
Braveheart Bio, Inc. (BRVE)
Director, 10% owner · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-08-07 | P, purchase reported on Form 4 | 1,666,667 | $30.0M | 2026-08-11 |
Corvus Pharmaceuticals, Inc. (CRVS)
Director, 10% owner · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-06-27 | S, sale reported on Form 4 | 1,176,332 | $4.9M | 2025-07-01 |
Damora Therapeutics, Inc. (GLTO)
10% owner · 1 filing · 9 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-04-13 | S, sale reported on Form 4 | 9,459 | $17.2K | 2023-04-17 |
| 2023-04-13 | S, sale reported on Form 4 | 3,784 | $6.9K | 2023-04-17 |
| 2023-04-13 | S, sale reported on Form 4 | 703 | $1.3K | 2023-04-17 |
| 2023-04-14 | S, sale reported on Form 4 | 2,091 | $3.9K | 2023-04-17 |
| 2023-04-14 | S, sale reported on Form 4 | 11,245 | $20.9K | 2023-04-17 |
| 2023-04-14 | S, sale reported on Form 4 | 28,110 | $52.3K | 2023-04-17 |
| 2023-04-17 | S, sale reported on Form 4 | 3,551 | $7.0K | 2023-04-17 |
| 2023-04-17 | S, sale reported on Form 4 | 8,878 | $17.5K | 2023-04-17 |
| 2023-04-17 | S, sale reported on Form 4 | 660 | $1.3K | 2023-04-17 |
Electra Therapeutics, Inc. (ETRA)
Director, 10% owner · 1 filing · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-09-21 | P, purchase reported on Form 4 | 333,333 | $5.0M | 2026-09-23 |
| 2026-09-21 | P, purchase reported on Form 4 | 1,000,000 | $15.0M | 2026-09-23 |
KNTE
Director, 10% owner · 1 filing · 4 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-05-04 | P, purchase reported on Form 4 | 83,459 | $229.5K | 2023-05-08 |
| 2023-05-04 | P, purchase reported on Form 4 | 312,991 | $860.7K | 2023-05-08 |
| 2023-05-05 | P, purchase reported on Form 4 | 490,511 | $1.4M | 2023-05-08 |
| 2023-05-05 | P, purchase reported on Form 4 | 490,512 | $1.4M | 2023-05-08 |
MBX Biosciences, Inc. (MBX)
Director, 10% owner · 1 filing · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-09-16 | P, purchase reported on Form 4 | 500,000 | $8.0M | 2024-09-17 |
| 2024-09-16 | P, purchase reported on Form 4 | 250,000 | $4.0M | 2024-09-17 |
PMV Pharmaceuticals, Inc. (PMVP)
10% owner · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2025-09-10 | S, sale reported on Form 4 | 500,000 | $900.0K | 2025-09-12 |
SCPH
10% owner · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-25 | P, purchase reported on Form 4 | 762,380 | $4.0M | 2022-11-29 |
SRRA
Director, 10% owner · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Scribe Therapeutics, Inc. (SCTX)
Director · 1 filing · 1 purchase or sale
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2026-07-27 | P, purchase reported on Form 4 | 1,000,000 | $15.0M | 2026-07-29 |
Shattuck Labs, Inc. (STTK)
Director · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
TCDA
Director, 10% owner · 1 filing · 3 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2022-11-22 | S, sale reported on Form 4 | 1,034,421 | $227.6K | 2022-11-25 |
| 2022-11-23 | S, sale reported on Form 4 | 5,617,300 | $1.2M | 2022-11-25 |
| 2022-11-25 | S, sale reported on Form 4 | 3,629,226 | $798.4K | 2022-11-25 |
Upstream Bio, Inc. (UPB)
Director, 10% owner · 1 filing · 2 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2024-10-15 | P, purchase reported on Form 4 | 165,000 | $2.8M | 2024-10-17 |
| 2024-10-15 | P, purchase reported on Form 4 | 660,000 | $11.2M | 2024-10-17 |
VRNA
Director · 1 filing · 4 purchases and sales
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2023-05-11 | S, sale reported on Form 4 | 80,000 | $1.8M | 2023-05-15 |
| 2023-05-12 | S, sale reported on Form 4 | 43,200 | $934.8K | 2023-05-15 |
| 2023-05-15 | S, sale reported on Form 4 | 345,313 | $6.9M | 2023-05-15 |
| 2023-05-15 | S, sale reported on Form 4 | 14,400 | $316.2K | 2023-05-15 |
Xtant Medical Holdings, Inc. (XTNT)
Director, 10% owner · 1 filing · 0 purchases and sales
No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.
Source
Counted from the Form 4 filings this reporting owner (SEC CIK 1055951) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms